| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.08. | Santen Pharmaceutical Co., Ltd. Q1 Income Rises | 1 | RTTNews | ||
| 05.08. | Santen Pharmaceutical Co., Ltd.: Santen Joins Inaugural Global Summit for Eye Health as High-Impact Partner | 883 | EQS Group (EN) | Santen Pharmaceutical Co., Ltd.
Santen Joins Inaugural Global Summit for Eye Health as High-Impact Partner 05-Aug-2026 / 10:30 CET/CEST
The issuer is solely responsible for the... ► Artikel lesen | |
| 12.05. | Santen Pharmaceutical Co. Q1 GAAP EPS of ¥104.99, revenue of ¥291.62B | 1 | Seeking Alpha | ||
| 12.05. | Santen Pharmaceutical Co., Ltd. Announces Increase In Full Year Income | 1 | RTTNews | ||
| SANTEN PHARMACEUTICAL CO LTD ADR Aktie jetzt für 0€ handeln | |||||
| 31.03. | Santen sharpens China focus under global development strategy | 2 | China Daily | ||
| 06.11.25 | Sydnexis, Inc.: Sydnexis Announces UK Approval of Ryjunea by Partner Santen to Slow Progression of Childhood Myopia | 556 | Business Wire | Sydnexis, Inc., (www.sydnexis.com), a biopharmaceutical company focused on pediatric progressive myopia (PPM), today noted its partner Santen's announcement that the UK Medicines and Healthcare products... ► Artikel lesen | |
| 05.11.25 | Santen Receives UK Approval for Ryjunea (low-dose atropine 0.1 mg/ml) to Slow Progression of Childhood Myopia | 799 | PR Newswire | First MHRA-approved low-dose atropine eye drop to slow the progression of myopia (short-sightedness) in children aged 3-14 years with a progression rate of 0.5 D or more per year and... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVARTIS | 136,00 | +0,10 % | Novo Nordisk gegen Eli Lilly, Johnson & Johnson setzt auf Zelltherapie - wo entsteht der nächste Milliardenmarkt? | ||
| MPH HEALTH CARE | 24,100 | +0,84 % | Dividendenbekanntmachungen (10.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADVANCE AUTO PARTS INC US00751Y1064 0,25 USD 0,2187 EUR ALPHA BANK SA ADR US02071M5076 0,0187 USD 0,0163 EUR AMERICAN EAGLE OUTFITTERS... ► Artikel lesen | |
| COMPASS PATHWAYS | 11,500 | 0,00 % | Vergiss Zulassungen! Wer zahlt für die Therapie? Diese 3 Biotech-Aktien zeigen, worauf es jetzt wirklich ankommt | ||
| HIGH TIDE | 2,085 | -0,95 % | High Tide Inc.: High Tide Announces Voting Results of Annual General and Special Meeting of Shareholders | CALGARY, AB, Aug. 12, 2026 /PRNewswire/ -- High Tide Inc. ("High Tide" or the "Company") (Nasdaq: HITI) (TSXV: HITI) (FSE: 2LYA), the high-impact, retail-forward enterprise built to deliver... ► Artikel lesen | |
| SHANGHAI FOSUN PHARMACEUTICAL | 1,869 | -2,53 % | FOSUN PHARMA Doses First Participant in China Phase I Trial of HTG siRNA Innovative Drug FXR0906 | ||
| SAVARA | 4,670 | -2,53 % | Savara Inc.: Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041 | -- In December 2025, Savara and PARI Were Granted a Joint European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI, Delivered Via PARI's Proprietary eFlow Nebulizer System... ► Artikel lesen | |
| PROMINO NUTRITIONAL SCIENCES | 0,005 | -84,62 % | Promino Nutritional Sciences, Inc.: Rejuvenate Muscle Health Expands its Position in the Emerging GLP-1 Muscle Health Category with U.S. Pharmacy Program and National E-Commerce Expansion | Top-tier U.S. grocery and pharmacy chain launches 662-store GLP-1 pharmacy merchandisingOne of North America's largest omnichannel retailers approves onboarding of Rejuvenate's complete eight-SKU... ► Artikel lesen | |
| EVOLUS | 7,136 | -0,67 % | Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo in the United States, Expanding Its Injectable Portfolio into Skin Quality | Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has entered into an exclusive licensing and... ► Artikel lesen | |
| ATYR PHARMA | 0,433 | -0,23 % | aTyr Pharma, Inc.: aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD | Company awaiting comments from FDA by the end of August 2026 on protocol submitted for planned Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis. Workforce reduction of approximately... ► Artikel lesen | |
| MINDWALK | 1,190 | 0,00 % | MindWalk Holdings Corp. Reports Fiscal 2026 Results: Revenue Up 46% as the Company Completes Its Pivot to Bio-Native AI Infrastructure | Full-year revenue rose 46% to $15.6 million with gross margin expanding to 59%; net loss narrowed by more than half as MindWalk sharpened its focus on the BioIntelligence infrastructure powering... ► Artikel lesen | |
| CIPHER PHARMACEUTICALS | 8,750 | 0,00 % | Cipher Pharmaceuticals verfehlt Umsatzprognose für Q2 2026, Aktie legt dennoch zu | ||
| STEVANATO GROUP | 19,300 | 0,00 % | Sage Park Acquires Balda C. Brewer, the California-based Contract Manufacturing Injection Molding Subsidiary From Stevanato Group S.p.A. | ANAHEIM, CA / ACCESS Newswire / August 4, 2026 / Craftech Holdco, a portfolio company of Sage Park, today announced the acquisition of Balda C. Brewer ("BCB"), the Ontario, California-based contract... ► Artikel lesen | |
| NIPPON KAYAKU | 10,900 | -0,91 % | Dividendenbekanntmachungen (30.03.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 77 BANK LTD JP3352000008 113 JPY 0,6124 EUR ACOM CO LTD JP3108600002 10 JPY 0,0542 EUR ADAMAS TRUST INC US6496048405 0,23 USD 0... ► Artikel lesen | |
| BAYER | 48,040 | -1,17 % | Bayer ist mehr als die Roundup-Wette | Bayer hat an der Börse lange fast nur über ein einziges Thema funktioniert: Glyphosat. Gute Pharmadaten, Agrarwachstum oder Sparprogramme wurden regelmäßig von neuen US-Rechtsrisiken überlagert. Im... ► Artikel lesen | |
| MERCK KGAA | 137,95 | -0,07 % | Bundeskartellamt gibt Übernahme von Bio-Techne durch Merck KGaA (Darmstadt) frei | Das Bundeskartellamt hat heute die geplante Übernahme des US-amerikanischen Biotechnologieunternehmens Bio-Techne, Minneapolis, durch die Merck KGaA aus Darmstadt freigegeben. Das Vorhaben ist auch... ► Artikel lesen |